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Abstract—Computer-Aided Drug Discovery research has
proven to be a promising direction in drug discovery. In recent
years, Deep Learning approaches have been applied to problems
in the domain such as Drug-Target Interaction Prediction and
have shown improvements over traditional screening methods.
An existing challenge is how to represent compound-target pairs
in deep learning models. While several representation methods
exist, such descriptor schemes tend to complement one another in
many instances, as reported in the literature. In this study, we pro-
pose a multi-view architecture trained adversarially to leverage
this complementary behavior by integrating both differentiable
and predefined molecular descriptors. We conduct experiments
on clinically relevant benchmark datasets to demonstrate the
potential of our approach.
Index Terms—Drug-Target Interaction, Bioactivity, Deep learn-
ing, Drug Discovery
I. INTRODUCTION
Over the years, drug discovery has predominantly trans-
formed from crude and serendipitous characteristics to a
well-structured and rational scientific paradigm. The paradox,
however, is that the growth experienced in the domain has not
made the identification of drugs any easier as attested to by
the high attrition rates and huge budgets typically involved in
the process [1]. Traditionally, in vitro screening experiments
are conducted in order to identify new interactions. However,
considering that there are about 1060 synthetically feasible
compounds, in silico or virtual screening alternatives are
mostly used for this process [2]. The two main in silico
approaches to Drug-Target Interaction (DTI) prediction are
docking simulations and machine learning approaches. Dock-
ing simulations utilize compound and target conformations to
discover binding sites whereas machine learning methods are
based on using features of compounds and/or targets, or their
similarities.
A central aspect in applying these computational models
is the featurization of compounds and biological targets into
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numerical vectors. This is achieved using molecular descrip-
tors which encode properties such as bonds, valence struc-
tures, sequence information, and other related properties [3].
Digitally, 2D structures of compounds are represented using
line notations such the Simplified Molecular Input Line Entry
System (SMILES) [4] whereas targets are represented using
sequences, and/or their conformations when available. These
digital forms are then used by toolkits (e.g. RDKit [5]) to
derive the molecular descriptors.
However, there exist several different kinds of molecular
descriptors in the literature with Extended Connectivity Fin-
gerprints (ECFP) being one of the widely used descriptors.
Considering that for a given compound, different descriptors
produce different properties which affect model performance,
this makes the choice a featurization method in model de-
velopment a significant one [6], [7]. In certain cases, the
performance of certain descriptors tend to be task related [3],
[8]. To this end, it is usual in the domain to find different
descriptors being combined as input to a model, an approach
referred to as Joint Multi-Modal Learning [9]. Nonetheless,
the unimodal features that are used in constructing the joint
representations tend to be constructed from pre-determined
descriptors.
In this study, we propose an integrated view predictive
architecture that is trained adversarially [10] for predicting
compound-target binding affinities. The motivation is that,
these descriptors tend to complement one another in many
cases and that the different modalities could provide an
in-depth perspective about a sample [3]. Additionally, the
enormity of the chemical space connotes that task-specific
representation of compounds is a desideratum of DTI predic-
tion research [11]. Therefore, our departure from constructing
joint representations exclusively with predefined descriptors
to leveraging differential feature learning and such predefined
descriptors dovetails into the concept of tailoring DTI tasks to
their input space.
The subsequent sections are organized as follows: section II
highlights related work of our study, section III discusses our
proposed model, section IV presents the experiments design
of our study. We also discuss the results of our experiments
in section V and draw our conclusions in section VI.
II. RELATED WORK
The concept of utilizing multiple unimodal descriptors
toward predicting bioactivity has been well studied in the
literature. Since different descriptors tend to represent different
properties of compounds [6], integrating these descriptors
has been considered in several studies. In [12], 18 different
chemical descriptors are benchmarked on DTI prediction tasks
and their findings reveal that integrating multiple descriptors
typically improves model performance. The works of Soufan
et al [13], [14] also corroborate this observation. Hence, the
combination enables the participating descriptors to create
informative feature vectors.
While these studies espouse integrating multiple chemical
descriptors, existing studies have mostly employed predefined
feature sets, such as structure-based fingerprints and pharma-
cophore descriptors proposed by experts in the domain, on
DTI prediction problems. Recent studies have also proposed
end-to-end compound descriptor learning functions toward
ensuring a closer relationship between the learning objective
and the input space [11], [15], [16]. Although several studies
have approached DTI prediction as a binary classification
problem [17], the nature of bioactivity is deemed to be contin-
uous [18]. In [19], a DL model using ECFP (with diameter 4)
is compared to a Molecular Graph Convolution (GraphConv)
model on predicting binding affinities. In both cases, target
information, in the form of Protein Sequence Composition
(PSC), is combined with the descriptor of a compound for
predicting the binding strengths. The work in [19] also shows
that using DL methods for predicting bioactivity generally
leads to better performance than kernel- and gradient boosting
machines-based methods [18], [20].
We propose a predictive generative adversarial network [10]
architecture, for leveraging the complementary relationship
between the seemingly disparate featurization methods in the
domain. We show that our approach generally improves the
findings in [19].
III. MODEL
A. Problem Formulation
We consider the problem of predicting a real-valued binding
affinity yi between a given compound ci and target pi, i ∈ R.
The compound ci is represented as a SMILES [4] string
whereas the target pi is represented as an amino acid sequence.
The target feature vector is constructed using Protein Sequence
Composition (PSC), which comprises of the Amino Acid Com-
position (AAC), Dipeptide Composition (DC), and Tripeptide
Composition (TC), using ProPy [21]. The SMILES string of
ci is an encoding of a chemical graph structure di = {Vi, Ei},
where Vi is the set of atoms constituting ci and Ei is a set
of undirected chemical bonds between these atoms. While
predefined fingerprints are computed by directly examining
di, descriptor learning functions like GraphConv [22] take as
input di and learn the numerical representation of ci using
backpropagation.
B. Proposed Architecture
The proposed Integrated Views Predictive Generative Ad-
verserial Network (IVPGAN) for DTI, is shown in figure 1.
Given a predefined descriptor vector vci of ci, chemical graph
structure di, and the PSC vector v
p
i of pi, we optimize the
following mean squared error (MSE) loss,
argmin
θf ,θg
N∑
i=0
(yi − f([v
c
i , g(di; θ
g), vpi ]; θ
f ))2 (1)
where θf and θg are trainable parameters.
Thus, we form a joint representation of the query entities ci
and pi by concatenating the predefined molecular descriptor,
the outputs of the parameterized descriptor learning function
g(·; θg), and the PSC feature vector of pi We refer to this
joint representation as the Combined Input Vector (CIV). Since
equation 1 is able to estimate the bias and variance of an
estimator, this makes it a good fit for real-valued models.
However, the squared loss is sensitive to the overall de-
parture of the samples and tends to represent the output
distribution by placing masses in parts of the space with low
densities. In computer vision problems, this results in a blur-
ring effect. Therefore, we follow Lotter et. al [10] to train our
DTI prediction model adversarially by applying Adversarial
Loss (AL). Specifically, we view the model accepting CIV
input as generating a binding strength between a given pair,
as against a vanilla prediction model. This perspective enables
us to leverage techniques in Generative Adverserial Networks
(GANS) [23] to mitigate the aforementioned problem of
equation 1. Also, models trained adverserially are able to learn
the structured patterns in a distribution [10].
To this end, given a set of generated binding strengths
yˆ = {yˆ1, yˆ2, ..., yˆN} produced by a generator G and their
corresponding ground truths y = {y1, y2, ..., yN}, we con-
struct two neighborhood alignment datasets for the adversarial
training phase.
Let Y = {yˆ,y} be the set of predicted and label vectors.
We construct the data matrix M (l) from Y (l), 0 < l ≤ 2, as:
M
(l)
m,k =


a1,1 a1,2 · · · a1,k
a2,1 a2,2 · · · a2,k
...
...
. . .
...
am,1 am,2 · · · am,k

 (2)
whereM
(l)
i,:k =
[
|Y
(l)
i − Y
(l)
1 |, |Y
(l)
i − Y
(l)
2 |, · · · , |Y
(l)
i − Y
(l)
N |
]
:k
such that ai,j ≤ ai,j+1, where k ≤ N and [· · · ]:k denotes
array slicing up to the kth element. Intuitively, each row is a
vector whose elements are the magnitudes of the differences
a specific datapoint has with its closest-k neighbors in its
corresponding distribution.
TABLE I: Dataset sizes
Dataset
Number of
compounds
/drugs
Number
of targets
Total number
of pair samples
Filter
threshold
used
Davis 72 442 31824 6
Metz 1423 170 35259 1
KIBA 3807 408 160296 6
This information serves as the feature vectors of the data-
points for adversarial training. The learning objective then is:
f(·; θf ) is to generate binding strengths that are closer to their
ground truths and also have a similar neighborhood structure
as the labels distribution. The resulting composite objective
for the minimization operation then takes the form:
LG = L
MSE
G + λL
AL
G (3)
where the adversarial training elements for minimization are:
LALD = Ex∼p [−logD(x)] + Ex∼G [−log(1−D(x))] (4)
LALG = Ex∼G [−logD(x)] (5)
The distributions p and G of equations 4-5 are represented by
the matrices constructed from the labels and predicted values,
respectively. λ is a hyperparameter that is used to control the
combination of MSE and AL losses of the generator.
In what follows, we demonstrate how this composite loss,
together with the integration of the predefined descriptors and
end-to-end descriptor learning, improves the model (generator)
skill at predicting the binding strengths between a given
compound-target pair.
IV. EXPERIMENTS PROTOCOL
In this section, we present the design of our experiments
and baselines. We also provide our source code and ancillary
files at https://github.com/bbrighttaer/ivpgan.
A. Datasets and Implementations
The benchmark datasets used are the Metz [24], KIBA [25],
and Davis [26] datasets as provided by the work in [19]. In
their work, they applied a filter threshold to each dataset for
which compounds and targets with total number of samples
not above the threshold are removed. The summary of these
datasets are presented in table I.
In our experiments, the ECFP8 [27] and Molecular Graph
Convolution (GraphConv) [22] serve as representatives of
predefined molecular descriptors and differentiable molecular
descriptors, respectively. We used the data loading and met-
rics procedures provided by [19] (with modifications where
necessary) and implemented all models using the Pytorch
framework. All our experiments were spread over the servers
described in table II.
B. Baselines
We compare our proposal to the parametric models proposed
in [19]. In our implementation of the ECFP-PSC architecture,
we used the ECFP8 variant, other than the ECFP4 used
in [19] and in several previous studies. In our preliminary
TABLE II: Simulation hardware specifications
Model # Cores
RAM
(GB)
Avail.
GPUs
# GPUs
used
Intel Xeon
CPU E5-2687W
48 128
1 GeForce
GTX 1080
1
Intel Xeon
CPU E5-2687W
24 128
4 GeForce
GTX 1080Ti
2
experiments of comparing ECPF4-PSC and ECFP8-PSC ar-
chitectures, ECFP8 variant mostly outperformed the ECFP4
model. This finding corroborates the view in [27] that while
fewer iterations could lead to good performances in similarity
and clustering tasks, activity prediction models tend to perform
better with greater structure details.
C. Model Training and Evaluation
In our experiments, we used a 5-fold double Cross Val-
idation (CV) model training approach in which three main
splitting schemes were used:
• Warm split: Every drug or target in the validation set is
encountered in the training set.
• Cold-drug split: Compounds in the validation set are
absent from the training set.
• Cold-target split: Targets in the validation set are absent
from the training set.
Since cold-start predictions are typically found in DTI use
cases, the cold splits offer an interesting and more challenging
validation schemes for the trained models.
As regards evaluation metrics, we measure the Root Mean
Squared Error (RMSE) and Pearson correlation coefficient
(R2) on the validation sets in each CV-fold. Additionally, we
measure the Concordance Index (CI) on the validation set as
proposed by [18].
We follow the averaging CV approach where the reported
metrics are the averages across the different folds. We also
repeat the CV evaluation for different random seeds to mini-
mize randomness. Consequently, all statistics are also averaged
across such seeds. Hyperparameters were searched for on the
warm split of the davis dataset using the Bayesian optimization
API of scikit-optimize.
V. RESULTS AND DISCUSSION
In tables III-V, we present the RMSE, CI, and R2 values as
measured on the best trained models on each of the benchmark
datasets, respectively. The standard deviation is placed beneath
the mean value of each case.
Firstly, model complexity and data sizes were influential
in model performances. While the IVPGAN and GraphConv-
PSC models took longer training times due to the large number
of parameters, ECFP8-PSC took much less time to train. The
simplicity of ECFP8-PSC also ensured less overfitting with
adequate regularization in the face of fewer samples in a
number of cases.
Notwithstanding the foregoing observation, IVPGAN
mostly achieved the best results than the baseline models, with
the GraphConv-PSC being outperformed by the ECFP8-PSC
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Fig. 1: An integrated architecture of different views for DTI prediction using a Predictive GAN approach.
model. Also, just as there exists a general trend of increasing
difficulty of prediction from warm split to cold target split
in [19], our implementations experienced this behavior as well
albeit, with significant improvements in many cases.
Furthermore, there exist a similar trend across tables III-
V. Feng et. al [19] observed that, for datasets where there
are more samples of compounds than targets, cold drug split
performances had the tendency to perform better than cold
target splits with the reverse being true. However, in our
experiments, we observed that such a relationship may be
tenuous, at best, and that model skill seem to depend more
on model capacity and hyperparameters used for training. In
the case of warm splits results, our experiments align with the
observation in [19] that they are always better than both cold
drug and cold target split performances due to the variation
in sample sizes. Indeed, it can be observed that cold target
split proved to be the most challenging splitting scheme for
all models in our experiments.
Additionally, on the KIBA dataset, although the number of
compounds significantly outweighs that of targets, the differ-
ence in cold target and cold drug performances, as measured
on IVPGAN, is not as pronounced as seen in the baseline
models. Thus, with IVPGAN, diversity in compound features
seem more necessary for richer representation of compound-
target samples.
While IVPGAN mostly outperformed the baseline models,
and especially so in the cold split schemes, it was mostly
outperformed on the Metz dataset. Aside a possible overfitting
due to sample size (also for GraphConv), the hyperparameters
used may be less suited for the Metz dataset and its CV split
schemes.
We also conducted qualitative investigations into the
prediction performances of all models trained herein.
The resulting scatter and joint plots could be seen at
https://github.com/bbrighttaer/ivpgan. These plots align with
the trends identified in tables III-V. We realized that IVPGAN
is able to learn the labels distribution better than the baseline
models in most of the cases and more so in the cold target
TABLE III: Performance of regression on benchmark datasets
measured in RMSE.
RMSE
Datatset CV split type ECFP8 GraphConv IVPGAN
Davis
Warm
0.2216
±0.082
0.3537
±0.053
0.2014
±0.043
Cold drug
0.3978
±0.105
0.4751
±0.123
0.2895
±0.163
Cold target
0.5517
±0.088
0.5752
±0.101
0.2202
±0.139
Metz
Warm
0.3321
±0.057
0.5537
±0.033
0.5529
±0.033
Cold drug
0.3778
±0.097
0.5711
±0.057
0.5477
±0.064
Cold target
0.6998
±0.065
0.7398
±0.047
0.5745
±0.054
KIBA
Warm
0.4350
±0.086
0.5604
±0.120
0.4003
±0.082
Cold drug
0.4502
±0.128
0.552
±0.156
0.4690
±0.132
Cold target
0.6645
±0.137
0.7555
±0.153
0.4486
±0.106
TABLE IV: Performance of regression on benchmark datasets
measured in CI
Concordance Index
Dataset CV split type ECFP8 GraphConv IVPGAN
Davis
Warm
0.9647
±0.020
0.9335
±0.011
0.9729
±0.008
Cold drug
0.9099
±0.049
0.8784
±0.052
0.9493
±0.044
Cold target
0.8683
±0.033
0.8480
±0.038
0.9631
±0.036
Metz
Warm
0.8923
±0.025
0.7968
±0.027
0.7913
±0.029
Cold drug
0.8730
±0.044
0.7850
±0.040
0.7894
±0.042
Cold target
0.7304
±0.039
0.7084
±0.041
0.7776
±0.038
KIBA
Warm
0.8322
±0.024
0.7873
±0.029
0.8433
±0.023
Cold drug
0.8132
±0.047
0.7736
±0.048
0.8070
±0.051
Cold target
0.7185
±0.044
0.6661
±0.052
0.8234
±0.044
TABLE V: Performance of regression on benchmark datasets
measured in R2.
R2
Dataset CV split type ECFP8 GraphConv IVPGAN
Davis
Warm
0.9252
±0.061
0.8254
±0.039
0.9449
±0.021
Cold drug
0.7573
±0.171
0.6773
±0.159
0.8635
±0.151
Cold target
0.5916
±0.120
0.5423
±0.121
0.9059
±0.121
Metz
Warm
0.8637
±0.057
0.6279
±0.075
0.6285
±0.078
Cold drug
0.8124
±0.117
0.5860
±0.120
0.6166
±0.120
Cold target
0.4259
±0.121
0.3619
±0.112
0.5931
±0.106
KIBA
Warm
0.7212
±0.072
0.5513
±0.097
0.7658
±0.065
Cold drug
0.6677
±0.137
0.5026
±0.152
0.6475
±0.142
Cold target
0.3648
±0.128
0.1910
±0.088
0.7056
±0.113
CV schemes when there are significantly fewer targets. The
realization that the GraphConv-PSC model is not able to
properly model the target distribution for smaller datasets, with
the ECFP8-PSC model being mostly less so, highlights the
potential of IVPGAN.
The neighborhood alignment dataset in the adversarial train-
ing also enables the reduction of residues in most of the scatter
plots. In summary, these results and findings demonstrate the
feasibility and effectiveness of our approach to DTI prediction.
VI. CONCLUSION
In this study, we have discussed the use of DL models
in DTI prediction and emphasized the significance of the
choice of featurization schemes in model training. Using
the ECFP8-PSC and GraphConv-PSC models as baselines,
we have demonstrated that the IVPGAN approach results in
improved model skill in most challenging use cases such as
cold target splits.
Future studies could examine how coordinated multi-view
representation learning mechanisms compare to the joint ap-
proach adopted in this study. In addition, other proposed GAN
training techniques could be adopted to address problems
associated with GAN training.
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